Trial Profile
A phase Ia /Ib study of vaccination with NY-ESO-1 protein, Poly ICLC and mogamulizumab in patients with Adult T cell leukemia/lymphoma expressing NY-ESO-1 antigen
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Cancer vaccine NY-ESO-1; Poly ICLC
- Indications Adult T-cell leukaemia-lymphoma
- Focus Adverse reactions
- 05 Jun 2015 New trial record